EV-077 is a more potent inhibitor of platelet function than aspirin

Journal of Thrombosis & Haemostasis

EV-077 is one of our legacy pharma programs. In this study the platelet function of EV-077 is compare to aspirin. Out-licensed to Norway's Serodus ASA, EV-077 is being developed for diabetic nephropathy, a progressive kidney disease stemming from diabetes.

Journal of Thrombosis & Haemostasis

Sign up to receive our
Press Releases!

Sign up